Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
50%
Ph phase_3
2
50%

Phase Distribution

2

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Completed2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (50.0%)
Phase 32 (50.0%)

Trials by Status

completed250%
recruiting250%

Recent Activity

2 active trials
Showing 4 of 4
completedphase_1

Effect of Renal Impairment on Enpatoran Pharmacokinetics

NCT06589713
recruitingphase_3

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

NCT07332481
recruitingphase_3

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

NCT07355218
completedphase_1

Enpatoran Human Mass Balance and Absolute Bioavailability Study

NCT05110027

Clinical Trials (4)

Showing 4 of 4 trials
NCT06589713Phase 1

Effect of Renal Impairment on Enpatoran Pharmacokinetics

Completed
NCT07332481Phase 3

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Recruiting
NCT07355218Phase 3

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

Recruiting
NCT05110027Phase 1

Enpatoran Human Mass Balance and Absolute Bioavailability Study

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4